Pitolisant: Pediatric First Approval
This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy.PMID:37233887 | DOI:10.1007/s40272-023-00575-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 26, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Pitolisant: Pediatric First Approval
This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy.PMID:37233887 | DOI:10.1007/s40272-023-00575-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 26, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Pitolisant: Pediatric First Approval
This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy.PMID:37233887 | DOI:10.1007/s40272-023-00575-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 26, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Pitolisant: Pediatric First Approval
This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy.PMID:37233887 | DOI:10.1007/s40272-023-00575-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 26, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Pitolisant: Pediatric First Approval
This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy.PMID:37233887 | DOI:10.1007/s40272-023-00575-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 26, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Pitolisant: Pediatric First Approval
This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy.PMID:37233887 | DOI:10.1007/s40272-023-00575-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 26, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES Survey
CONCLUSIONS: This is the first characterization of P-CHE among pediatric dermatologists in the United States and Canada. This assessment may prove useful in designing further investigations including prospective studies of P-CHE epidemiology, morphology, nomenclature, and management.PMID:37225932 | DOI:10.1007/s40272-023-00574-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 24, 2023 Category: Pediatrics Authors: Michael A Haft Helen H Park Stephanie S Lee Jessica M Sprague Amy S Paller Colleen H Cotton Jacob P Thyssen Lawrence F Eichenfield Source Type: research
Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES Survey
CONCLUSIONS: This is the first characterization of P-CHE among pediatric dermatologists in the United States and Canada. This assessment may prove useful in designing further investigations including prospective studies of P-CHE epidemiology, morphology, nomenclature, and management.PMID:37225932 | DOI:10.1007/s40272-023-00574-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 24, 2023 Category: Pediatrics Authors: Michael A Haft Helen H Park Stephanie S Lee Jessica M Sprague Amy S Paller Colleen H Cotton Jacob P Thyssen Lawrence F Eichenfield Source Type: research
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
Paediatr Drugs. 2023 May 19. doi: 10.1007/s40272-023-00569-8. Online ahead of print.ABSTRACTHistiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim-Chester disease, juvenile xanthogranuloma, malignant histiocytoses, and Rosai-Dorfman-Destombes disease. These histiocytic disorders are a diverse group of disorders with different presentations, management, and prognosis. This review focuses on these histiocytic disorders and the role of pathological ERK signaling due to somatic mutations in the mitoge...
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Ashley V Geerlinks Oussama Abla Source Type: research
Cardiac Hypertrophy Associated with Insulin Therapy in Extremely Preterm Infants
CONCLUSIONS: Our case series supports the association between the development of CH and insulin therapy in extremely preterm infants and suggests further caution and the need for echocardiographic monitoring when treating these fragile patients with insulin.PMID:37204612 | DOI:10.1007/s40272-023-00571-0 (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Carlo Dani Michele Luzzati Iuri Corsini Chiara Poggi Venturella Vangi Caterina Coviello Simone Pratesi Source Type: research
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
Paediatr Drugs. 2023 May 19. doi: 10.1007/s40272-023-00569-8. Online ahead of print.ABSTRACTHistiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim-Chester disease, juvenile xanthogranuloma, malignant histiocytoses, and Rosai-Dorfman-Destombes disease. These histiocytic disorders are a diverse group of disorders with different presentations, management, and prognosis. This review focuses on these histiocytic disorders and the role of pathological ERK signaling due to somatic mutations in the mitoge...
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Ashley V Geerlinks Oussama Abla Source Type: research
Cardiac Hypertrophy Associated with Insulin Therapy in Extremely Preterm Infants
CONCLUSIONS: Our case series supports the association between the development of CH and insulin therapy in extremely preterm infants and suggests further caution and the need for echocardiographic monitoring when treating these fragile patients with insulin.PMID:37204612 | DOI:10.1007/s40272-023-00571-0 (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Carlo Dani Michele Luzzati Iuri Corsini Chiara Poggi Venturella Vangi Caterina Coviello Simone Pratesi Source Type: research
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
Paediatr Drugs. 2023 May 19. doi: 10.1007/s40272-023-00569-8. Online ahead of print.ABSTRACTHistiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim-Chester disease, juvenile xanthogranuloma, malignant histiocytoses, and Rosai-Dorfman-Destombes disease. These histiocytic disorders are a diverse group of disorders with different presentations, management, and prognosis. This review focuses on these histiocytic disorders and the role of pathological ERK signaling due to somatic mutations in the mitoge...
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Ashley V Geerlinks Oussama Abla Source Type: research
Cardiac Hypertrophy Associated with Insulin Therapy in Extremely Preterm Infants
CONCLUSIONS: Our case series supports the association between the development of CH and insulin therapy in extremely preterm infants and suggests further caution and the need for echocardiographic monitoring when treating these fragile patients with insulin.PMID:37204612 | DOI:10.1007/s40272-023-00571-0 (Source: Paediatric Drugs)
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Carlo Dani Michele Luzzati Iuri Corsini Chiara Poggi Venturella Vangi Caterina Coviello Simone Pratesi Source Type: research
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
Paediatr Drugs. 2023 May 19. doi: 10.1007/s40272-023-00569-8. Online ahead of print.ABSTRACTHistiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim-Chester disease, juvenile xanthogranuloma, malignant histiocytoses, and Rosai-Dorfman-Destombes disease. These histiocytic disorders are a diverse group of disorders with different presentations, management, and prognosis. This review focuses on these histiocytic disorders and the role of pathological ERK signaling due to somatic mutations in the mitoge...
Source: Paediatric Drugs - May 19, 2023 Category: Pediatrics Authors: Ashley V Geerlinks Oussama Abla Source Type: research
